A Single Molecule Carrier for Ocular Posterior Segment Diseases

Xiao-Ling Zhang,Yu-Xin Yue,Yang,An-Kang Ying,Rong Ma,Jie Chen,Fang-Yuan Chen,Xiao-Yun Hou,Yu-Chen Pan,Da-Zhuang Ren,Tao Yang,Zhi-Qing Li,Dong-Sheng Guo
DOI: https://doi.org/10.1016/j.jconrel.2024.10.052
2024-01-01
Abstract:Eye drops are envisaged as the most promising non-invasive formulation for the treatment of the ocular posterior segment diseases, while it is hindered by a series of complex ocular barriers, both static and dynamic in nature. In this context, we propose a single molecule nanomedicine based on host-guest chemistry to achieve highly efficient drug delivery targeted to ocular posterior segment. Sulfonated azocalix[4]arene (SAC4A) serves as the single molecule carrier, owing the multiple features of small size (24.0 Å in length, 21.2 Å in width, 14.8 Å in height with a Van der Waals volume of 930 Å3), negative charge, hydrophilicity, loading universality and hypoxia-triggered release. As a proof-of-concept, an eye drop formed by the complexation of SAC4A with sunitinib (SUN) is prepared to treat wet age-related macular degeneration (wAMD). SAC4A successfully transports SUN to the ocular posterior segment (the amount of SUN reaching the retinal-choroid tissue in the SUN@SAC4A group was 2.47 times larger than that in the SUN group at 30 min), significantly enhancing its anti-choroidal neoangiogenesis effect of SUN to wAMD, which played a key role in the treatment. We believe that the single molecule nanomedicine paradigm is highly amenable for treating various ocular posterior segment diseases in the future.
What problem does this paper attempt to address?